Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 495 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botox Clear all
Completed Phase 1 Interventional

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

NCT05496335
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Newport Beach, California • San Diego, California • Greenwood Village, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Not applicable Interventional

EMG Guided Botulinum Toxin Type A Injections for Refractory High Tone Pelvic Floor Dysfunction

NCT01323829
View directory record Official record
Conditions
High Tone Pelvic Floor Dysfunction
Interventions
EMG Guidance of Injection
Other
Lead sponsor
Pelvic and Sexual Health Institute
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 20, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT02973269
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
daxibotulinumtoxin type A, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 20, 2026, 9:03 AM EDT
Completed No phase listed Observational

Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

NCT02557971
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Davis, California • Irvine, California • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

NCT01767519
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 4 Interventional

Myobloc Atrophy Study

NCT02052024
View directory record Official record
Conditions
Spasticity Secondary to Either a Disorder or Trauma, Spinal Cord Injury (SCI), Brain Injury, Tumor, Stroke
Interventions
Botox, MYOBLOC
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 4 Interventional

Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy

NCT03701919
View directory record Official record
Conditions
Bariatric Surgery, Postoperative Nausea and Vomiting
Interventions
Botulinum toxin pyloroplasty, Normal saline pyloric injection
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 20, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Dysport in Vulvodynia Phase II Study

NCT03598777
View directory record Official record
Conditions
Vulvodynia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

NCT00910845
View directory record Official record
Conditions
Overactive Bladder
Interventions
onabotulinumtoxinA, normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 20, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the Use of Botox on Acne

NCT00765375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Botulinum Neurotoxin Type A, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

NCT04148872
View directory record Official record
Conditions
Synkinesis
Interventions
Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation
Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

NCT03617367
View directory record Official record
Conditions
Cervical Dystonia
Interventions
daxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

NCT01575054
View directory record Official record
Conditions
Muscle Spasticity
Interventions
botulinum toxin Type A, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 85 Years
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Downey, California • Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

NCT05158166
View directory record Official record
Conditions
Adductor Spasmodic Dysphonia, Voice Disorders, Spasmodic Dysphonia
Interventions
DaxibotulinumtoxinA
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 20, 2026, 9:03 AM EDT
Recruiting Phase 3 Interventional

Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis

NCT05990881
View directory record Official record
Conditions
Carpometacarpal Sprain, Thumb Sprain, Clostridium; Botulinum
Interventions
Botulinum toxin, Standard-of-care corticosteroid injections
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 20, 2026, 9:03 AM EDT
Not listed Phase 1 Interventional

New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain

NCT02008136
View directory record Official record
Conditions
Cervicalgia, Low Back Pain
Interventions
Botulinum Toxins
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 20, 2026, 9:03 AM EDT
Completed No phase listed Observational

Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

NCT03043287
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Shreveport, Louisiana • Baltimore, Maryland • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 20, 2026, 9:03 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444
View directory record Official record
Conditions
Chronic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

NCT05330078
View directory record Official record
Conditions
Keloid
Interventions
Botulinum toxin type A, Vehicle
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

NCT01391312
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
botulinum toxin Type A, normal saline (placebo)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
East Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

NCT05784363
View directory record Official record
Conditions
Enlarged Pores, Sebum Production
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
21 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Coral Gables, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

NCT01753336
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 20, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03960957
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA, Placebo
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Redondo Beach, California • San Diego, California • Westport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 20, 2026, 9:03 AM EDT